The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
Open accessAbstract
Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disease of unknown etiology. Recently, it has been reported that imatinib mesylate (Gleevec), an inhibitor of Bcr-Abl kinase useful in the treatment of chronic myeloid leukemia, is also effective in treating HES; however, the molecular target of imatinib in HES is unknown. This report identifies a genetic rearrangement in the eosinophilic cell line EOL-1 that results in the expression of a fusion protein comprising an N-terminal region encoded by a gene of unknown function with the GenBank accession number NM_030917 and a C-terminal region derived from the intracellular domain of the platelet-derived growth factor receptor α (PDGFRα). The fusion gene was also detected in blood cells from two patients with HES. We propose naming NM_030917 Rhe for R earranged in h yper e osinophilia. Rhe-PDGFR α fusions result from an apparent interstitial deletion that links Rhe to exon 12 of PDGFR α on chromosome 4q12. The fusion kinase Rhe-PDGFRα is constitutively phosphorylated and supports IL-3-independent growth when expressed in BaF3 cells. Proliferation and viability of EOL-1 and BaF3 cells expressing Rhe-PDGFR α are ablated by the PDGFRα inhibitors imatinib, vatalanib, and THRX-165724.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Cited by
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Eosinophilic gastrointestinal disorders (EGID)
Rothenberg, M. E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.047 · Cited by 923
Eosinophils: Biological Properties and Role in Health and Disease
HOGAN, S. P., ROSENBERG, H. F., MOQBEL, R., PHIPPS, S., FOSTER, P. S., LACY, P., KAY, A. B., & ROTHENBERG, M. E. (2008) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.02958.x · Cited by 834
Translation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Metadata
- Authors
- Griffin, J. H., Leung, J., Bruner, R. J., Caligiuri, M. A., & Briesewitz, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-06-13
- Volume
- 100
- Issue
- 13
- Pages
- 7830-7835
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2090045594
- Cited by
- 202
- References
- 2
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. https://app.cochat.ai/papers/10.1073/pnas.0932698100
- The paper
- Griffin, J. H., Leung, J., Bruner, R. J., Caligiuri, M. A., & Briesewitz, R. (2003). Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0932698100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.